Issue of Equity and Total Voting Rights

RNS Number : 1660X

Angle PLC

26 August 2015

 



ANGLE plc

("ANGLE" or "the Company")

Issue of Equity and Total Voting Rights

ANGLE plc (AIM:AGL and OTCQX:ANPCY), the specialist medtech company, announces that it has received notice from a former employee to exercise options over 4,000 ordinary shares of 10p each in the Company.

Accordingly the Company has allotted 4,000 new ordinary shares of 10p each ("New Ordinary Shares") in the capital of the Company. The New Ordinary Shares rank pari passu with the existing ordinary shares in the Company. An application has been made for the New Ordinary Shares to be admitted to trading on AIM and admission is expected to take place at 8.00 am on 2 September 2015. Following this allotment, the total issued share capital of the Company is 58,978,338 ordinary shares. The figure of 58,978,338 Ordinary Shares may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the Company under the FCA's Disclosure and Transparency Rules.

For further information:

ANGLE plc	01483 685830
Andrew Newland, Chief Executive Ian Griffiths, Finance Director
Cenkos Securities Stephen Keys, Dr Christopher Golden (Nominated adviser) Russell Kerr, Olly Baxendale (Sales)	020 7397 8900
FTI Consulting Simon Conway, Mo Noonan, Stephanie Cuthbert Kimberley Ha (US)	020 3727 1000 001 212 850 5612

Notes for editors

About ANGLE plc     

ANGLE is a specialist medtech company commercialising a disruptive platform technology that can capture cells circulating in blood, such as cancer cells, even when they are as rare in number as one cell in one billion blood cells, and harvest the cells for analysis.

ANGLE's cell separation technology, known as the Parsortix system, harvests the cells of interest through a liquid biopsy, with the patient only experiencing a simple blood test. Parsortix is the subject of two granted US patents, granted patents in China and Australia and three extensive families of patents being progressed worldwide. The system is based on a microfluidic device that captures cells based on a combination of their size and compressibility. The Parsortix system is established with strong positive evaluations from leading cancer research centres and is working with these cancer centres to demonstrate key applications. Parsortix has a CE Mark for Europe and FDA authorisation is in process for the US.

The analysis of the cells that can be harvested from patient blood with ANGLE's Parsortix system has the potential to help deliver personalised cancer care offering profound improvements in clinical and health economic outcomes in the treatment and diagnosis of various forms of cancer.

The Parsortix system is designed to be compatible with existing major medtech analytical platforms and to act as a companion diagnostic for major pharma in helping to identify patients that will benefit from a particular drug and then monitoring the drug's effectiveness.

ANGLE has established formal collaborations with world-class cancer centres and is working with these cancer centres to demonstrate key applications for its Parsortix non-invasive cancer diagnostic system as a liquid biopsy.  Details are available here http://www.angleplc.com/the-company/collaborators/

In addition to cancer, the Parsortix technology has the potential for deployment with several other important cell types in the future.

ANGLE began trading on the AIM market of the London Stock Exchange in March 2004 under the ticker symbol AGL. For more information visit www.angleplc.com

 

END

 

 

MSCPGUACRUPAGPQ